Form 4: TriSalus Life Sciences Executive Granted Stock Options and Restricted Stock Units

Jodi Devlin, Chief of Commercial Operations at TriSalus Life Sciences, received stock options and restricted stock units on January 27, 2025, according to a recent SEC filing.

Summary

• Jodi Devlin, Chief of Commercial Operations at TriSalus Life Sciences, filed a Form 4 with the SEC.
• The filing reports a transaction date of January 27, 2025.
• Devlin was granted 10,625 restricted stock units (RSUs) payable in common stock.
• These RSUs vest in four equal annual installments starting January 1, 2025, contingent on continued service.
• Devlin also received an employee stock option to purchase 63,750 shares at an exercise price of $5.30.
• One-fourth of the options vest on January 1, 2025, and the remaining shares vest monthly thereafter, subject to continued service, with an expiration date of January 26, 2035.
• Following the reported transactions, Devlin directly owns 63,750 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs is a standard practice and indicates confidence in the executive and the company's future performance. There are no explicitly negative aspects mentioned.

Positives

• The grant of RSUs and stock options aligns the executive's interests with those of the shareholders.
• The vesting schedules incentivize continued service and contribution to the company's success.

Future Outlook

The vesting schedules for the RSUs and stock options suggest an expectation of continued service and contribution from the executive.

Industry Context

Stock option and RSU grants are common forms of executive compensation in the life sciences industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options and RSUs to incentivize their leadership teams.
• The vesting schedules and exercise prices are typically benchmarked against industry peers to ensure competitiveness and alignment with performance goals.

Stakeholder Impact

• Shareholders may view the grant of stock options and RSUs as a positive sign, aligning management's interests with their own.
• Employees may be motivated by the potential for future equity value creation.

Key Dates